Bernstein Liebhard LLP Reports
According to a Wall Street Journal report published on October 23rd, Stryker Orthopaedics indicates that the cost of its hip replacement recall, which was issued on July 6, 2012 and affected some 20,000 Rejuvenate and ABG II modular-neck hip stems, could total anywhere from $700 million to $1.13 billion.*
Stryker’s previous estimations of its recall related expenses were between $400 million to $660 million, according to the WSJ report. As of October 2013, over 600 lawsuits alleging pain, swelling, metallosis and other complications stemming from the recalled metal hip replacements have been filed in federal and state courts throughout the U.S.
“As Stryker notes, the ultimate total cost to resolve these matters will depend on a number factors, including the number of patients seeking testing and treatment, the number of patients requiring revision surgeries and the amount of third-party insurance recoveries,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices, including the Stryker Rejuvenate and ABG II hip replacement implants. The Firm is also offering free and confidential case evaluations to individuals who may have been injured as a result of these devices.
Recent court records indicate that some 380 claims stemming from the Stryker recall, which was announced on July 2012 after post-surveillance data indicated the potential for the Rejuvenate and ABG II hip stems to fret and corrode at the modular-neck junction, have been filed in a multicounty litigation established in New Jersey. Cases filed in the proceeding underway in Atlantic County Superior Court similarly allege that Stryker failed to adequately warn about the potential for this complication to cause pain, swelling, metallosis and other complications in recipients. (In Re Stryker Rejuvenate Hip Stem and the ABG II Modular Hip Stem Litigation, No. 296)
Since its recall, the manufacturer has advised on its website that all individuals who received the Rejuvenate and ABG II hip devices undergo routine cross-sectional imaging and blood testing to monitor for elevated metal levels in the blood stream, whether or not they are experiencing symptoms associated with early device failure.**
At the federal court level, documents show approximately 290 similar actions against Stryker pending in a federal litigation established in the U.S. District Court, District of Minnesota. (In re: Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation, MDL No. 2441
Read more: http://www.digitaljournal.com/pr/1547354#ixzz2jVzlcSFt